{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Paut Kusturica M"],"funding":["Institute of Health Carlos III"],"pagination":["990"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12309166"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(1)"],"pubmed_abstract":["<h4>Purpose</h4>Attention-deficit/hyperactivity disorder (ADHD) is a prevalent childhood neurobehavioral disorder, imposing significant economic burdens on healthcare and society. This study aimed to examine healthcare resource utilisation and direct medical costs for paediatric ADHD patients in Catalonia, Spain, following their first ADHD treatment prescription.<h4>Methods</h4>Using real-world data from electronic healthcare records, this longitudinal register-based cohort study included all patients aged 6 to 18 years old who received a new centrally acting sympathomimetic treatment (ATC code N06BA) in the public healthcare system in Catalonia between 2016 and 2017. Healthcare resource utilisation and costs were analysed one year post-prescription, stratified by age (6-11, 12-14 and 15-1"],"journal":["BMC health services research"],"pubmed_title":["Assessing direct medical costs of children following a new prescription of ADHD medication."],"pmcid":["PMC12309166"],"funding_grant_id":["CP22/00029"],"pubmed_authors":["Paut Kusturica M","Rubio-Valera M","Lumbreras B","Huerta-Ramos ME","Sanchez-Vinas A","Aznar-Lou I"],"additional_accession":[]},"is_claimable":false,"name":"Assessing direct medical costs of children following a new prescription of ADHD medication.","description":"<h4>Purpose</h4>Attention-deficit/hyperactivity disorder (ADHD) is a prevalent childhood neurobehavioral disorder, imposing significant economic burdens on healthcare and society. This study aimed to examine healthcare resource utilisation and direct medical costs for paediatric ADHD patients in Catalonia, Spain, following their first ADHD treatment prescription.<h4>Methods</h4>Using real-world data from electronic healthcare records, this longitudinal register-based cohort study included all patients aged 6 to 18 years old who received a new centrally acting sympathomimetic treatment (ATC code N06BA) in the public healthcare system in Catalonia between 2016 and 2017. Healthcare resource utilisation and costs were analysed one year post-prescription, stratified by age (6-11, 12-14 and 15-1","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-03-27T15:29:41.72Z","creation":"2025-08-24T03:07:22.994Z"},"accession":"S-EPMC12309166","cross_references":{"pubmed":["40731352"],"doi":["10.1186/s12913-025-13106-9"]}}